What do sources say about thyrotropin releasing hormone doses?

500 mcg of Thyrotropin-Releasing Hormone (TRH) from a 0.5 mg vial mixed with 1 mL is 100 units on a U-100 syringe.

Every vial at a glance. Pick a cell to draw it on the syringe.

Concentration is the vial's amount over its water; units are the dose over the concentration, times 100, on a U-100 syringe.
Vial1 mL of water
0.5 mg0.5 mg/mL: 200 mcg is 40 units, 500 mcg is 100 units

The one TRH label in the pack with usable text, a compounded preparation's, gives adults 500 μg as a single intravenous bolus for a diagnostic thyroid function test, and children aged 6 to 16 years 7 μg/kg up to 500 μg.1

What the labelled vial holds and how it works out in units

The label lists TRH as a solution of 1 mL in a 5 mL vial holding 500 mcg of protirelin, for intravenous use after dilution with 1 mL of sterile water for injection.1 It gives no instruction for mixing a powder at home. Before dilution the vial holds 500 mcg in 1 mL, so 500 mcg is 100 units on a U-100 syringe, and 200 mcg, the lowest of the adult doses the label says have been used, is 40 units.1 After the label's 1 mL of sterile water, the 500 mcg sits in 2 mL, so 200 mcg is 80 units, and 500 mcg is 2 mL, more than a 1 mL syringe holds.1 The table, worked example and calculator below take the vial's 500 mcg in its own 1 mL of solution, before the label's dilution.1

500 mcg of Thyrotropin-Releasing Hormone (TRH) from a 0.5 mg vial mixed with 1 mL is 100 units on a U-100 syringe.

500 mcg of Thyrotropin-Releasing Hormone (TRH) from a 0.5 mg vial mixed with 1 mL is 100 units on a U-100 syringe.

What the label says about dose, schedule and route

The label lists TRH as an adjunct in the diagnostic assessment of thyroid function, in judging TSH suppression on T4 in goiter and in adjusting thyroid hormone dosage in primary hypothyroidism.1 It gives adults 500 μg, and children aged 6 to 16 years 7 μg/kg up to 500 μg, with larger doses unlikely to give a greater TSH response.1 It adds that doses between 200 and 500 μg have been used in adults, and that for infants and children up to 6 years experience is limited, with doses of 7 μg/kg administered.1 The dose is a bolus over 15 to 30 seconds with the patient lying supine.1 It describes a single test dose with a TSH blood sample before and 30 minutes after, says repeat dosing reduces the response, and, if the test is repeated, gives an interval of seven days before testing.1

The label's route is intravenous, and no label or trial in the pack gives a subcutaneous injection site; the Mitsumoto, 1986 record gives subcutaneous dosing without naming a site.12

What human trials used

The trials in the pack were mostly in patients, and the pack found no trial of a cycle of weeks on and off of TRH in healthy people.

TrialDose and schedulePeopleLength
Szuba, 20053500 microg intravenous at midnight, or saline, double-blindTwenty patients with bipolar type I or II major depression, 10 per armRated over a 48-hour period
Garbutt, 1994425, 100, 500 and 800 micrograms infused in ascending order at 3 to 7 day intervalsSeven women and six men with major depression, and five women and seven men as controlsNot stated
Van den Berghe, 19965Two intravenous 200 microgram boluses, 6 hours apart; dopamine continued (control) or stopped15 critically ill patients on dopamineNot stated
Benkert, 19766Oral 2 X 40 mg/day, or placebo, added to imipramine 3 X 50 mg/day, double-blind20 women and 10 men with a retarded-depressive syndrome2 weeks of a 20-day course
Mitsumoto, 19862Subcutaneous 25 mg daily, or saline; intravenous 500 mg, or placebo with norepinephrine, at 1-week intervals; crossover (units as printed)25 ALS patients (subcutaneous) and 16 ALS patients (intravenous)3 months (subcutaneous)
NCT00790296, 2006 to 20107Intravenous 0.5 mg and 1.5 mg, or saline, crossover11 enrolled, with cancer-related fatigueOutcomes 7 hours after infusion; terminated after interim analyses

The Mitsumoto record prints mg where micrograms are very likely meant, and the pack cannot correct it. In Weeke, 1975, in normal men (the source does not give how many), 30 mug was the smallest single dose with a maximal TSH and T3 response, and after six 30 mug injections 30 minutes apart the increase in TSH was two times, and in T3 three times, the maximal increase after single injections.8 In Vogt, 1978 (24 healthy adults given TRH intravenously, 25 given 40 mg orally), three 40 mg oral doses lowered TSH stimulation while T3 still rose comparably.9

How TRH is stored

The label says to store at room temperature and gives no condition or time for the diluted solution.1 No stability data for a reconstituted solution were found.

Frequently asked questions

Is TRH still sold as an approved product?

In a July 2002 notice, the American Thyroid Association said Ferring had halted Thyrel production to modify its manufacturing process, with no replacement expected until Thyrel returned, as no other company appeared to produce TRH; the pack found no current approved label.10

What does the label warn about?

The label says blood pressure frequently rises or falls briefly after TRH, with marked changes in a small number of patients, and, to minimize hypotension, gives supine positioning before, during and after administration.1 It says side effects were reported in about 50% of patients tested, generally minor and brief.1

Is TRH on the WADA list?

The WADA Prohibited List text in the pack does not name TRH.11

References

  1. DailyMed (Anazao Health). Thyrotropin-Releasing Hormone. 2012. dailymed.nlm.nih.gov
  2. Neurology (PubMed abstract). Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials. 1986. pubmed.ncbi.nlm.nih.gov
  3. Journal of clinical psychopharmacology (PubMed abstract). Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression. 2005. pubmed.ncbi.nlm.nih.gov
  4. Archives of general psychiatry (PubMed abstract). Dose-response studies with protirelin. 1994. pubmed.ncbi.nlm.nih.gov
  5. Critical care medicine (PubMed abstract). Thyrotropin-releasing hormone in critical illness: from a dopamine-dependent test to a strategy for increasing low serum triiodothyronine, prolactin, and growth hormone concentrations. 1996. pubmed.ncbi.nlm.nih.gov
  6. Arzneimittel-Forschung (PubMed abstract). [The effect of thyrotrophin releasing hormone versus placebo in combination with basic imipramine therapy of depressive patients]. 1976. pubmed.ncbi.nlm.nih.gov
  7. ClinicalTrials.gov (US National Library of Medicine). NCT00790296: Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related Fatigue. 2011. clinicaltrials.gov
  8. European journal of clinical investigation (PubMed abstract). The response of thyrotropin and triiodothyronine to various doses of thyrotropin releasing hormone in normal man. 1975. pubmed.ncbi.nlm.nih.gov
  9. Klinische Wochenschrift (PubMed abstract). Thyroid-stimulating hormone (tsh), triiodothyronine (t3) and thyroxine (t4) response to intravenous and oral stimulation with synthetic thyrotropin-releasing hormone (trh) in young healthy adults. 1978. pubmed.ncbi.nlm.nih.gov
  10. American Thyroid Association. Thyrel® TRH Temporarily Removed from Market | American Thyroid Association. 2002. thyroid.org
  11. WADA. WORLD ANTI-DOPING CODE. 2026. wada-ama.org